← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Paxvax, Inc.
San Diego, CA
$30,083,653
Total funding
8
Grants
Funding over time
peak $12.1M · FY2010–24$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$30,083,653 · 8
By mechanism
N01$23,494,669 · 2
R44$4,743,753 · 2
R43$1,147,286 · 3
N02$697,945 · 1
Investigators at Paxvax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Development of Technologies to Facilitate the use and Response of Vaccines$10,792,404
N01 · FY2013 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$3,804,245
N01 · FY2010 · AI
STAGED VACCINE DEVELOPMENT OF ADENIVIRUS-4 VECTORED VACCINE FOR HUMAN IMMUNODEFICIENCY VIRUS$3,239,039
N01 · FY2016 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$1,869,229
N01 · FY2011 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$1,651,037
N01 · FY2012 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$1,000,000
R44 · FY2012 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$1,000,000
R44 · FY2013 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model$971,235
R44 · FY2014 · AI
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP$971,055
R44 · FY2016 · AI
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP$801,463
R44 · FY2015 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$698,949
N01 · FY2015 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$651,370
N01 · FY2014 · AI
Development of Technologies to Facilitate the use and Response of Vaccines$593,314
N01 · FY2016 · AI
Ad4 vectored HIV-Env vaccines with improved immunogenicity$300,000
R43 · FY2010 · AI
Use of Spray-Drying as a Manufacturing Process for Oral Adenovirus Vaccine$298,464
R43 · FY2012 · GM
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2$287,214
R43 · FY2013 · AI
Replicating Ad4-HIV vaccine development based on improved HIV Env and GBV-C E2$261,608
R43 · FY2012 · AI
Extended Stability Program Testing of Two Adenoviral HIV Vaccine Candidates$235,429
N02 · FY2024 · AI
Extended Stability Program Testing of Two Adenoviral HIV Vaccine Candidates$232,637
N02 · FY2023 · AI
Extended Stability Program Testing of Two Adenoviral HIV Vaccine Candidates$229,879
N02 · FY2022 · AI